Evaluation of parasite subpopulations and genetic diversity of the msp1, msp2 and glurp genes during and following artesunate monotherapy treatment of Plasmodium falciparum malaria in Western Cambodia

Malaria Journal

Volumn 12, Issue 1, 2013, Pages

  Gosi, Panita ^a   Lanteri, Charlotte A ^a   Tyner, Stuart D ^a   Se, Youry ^b   Lon, Chanthap ^b   Spring, Michele ^a   Char, Mengchuor ^c   Sea, Darapiseth ^b   Sriwichai, Sabaithip ^a   Surasri, Sittidech ^a   Wongarunkochakorn, Saowaluk ^a   Pidtana, Kingkan ^a   Walsh, Douglas S ^a   Fukuda, Mark M ^a   Manning, Jessica ^a   Saunders, David L ^a   Bethell, Delia ^a  

^a ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^b Armed Forces Research Institute of Medical Sciences   (Cambodia)

^c National Center for Parasitology Entomology and Malaria Control   (Cambodia)

Author keywords

Artesunate; Cambodia; Genotype; glurp; Malaria; msp1; msp2; Plasmodium falciparum

Indexed keywords

ARTEMISININ; ARTESUNATE; GLUTAMATE RICH PROTEIN; MEROZOITE SURFACE PROTEIN 1; MEROZOITE SURFACE PROTEIN 2; PARASITE ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ALLELE; ARTICLE; BLOOD SAMPLING; CAMBODIA; CLINICAL ASSESSMENT; CONTROLLED STUDY; DATA ANALYSIS SOFTWARE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENE FREQUENCY; GENETIC ANALYSIS; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALARIA FALCIPARUM; MALE; META ANALYSIS; MONOTHERAPY; PLASMODIUM FALCIPARUM; PROTOZOAL GENETICS; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SINGLE DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIGENS, PROTOZOAN; ANTIMALARIALS; ARTEMISININS; CAMBODIA; FEMALE; GENETIC VARIATION; GENOTYPE; HUMANS; MALARIA, FALCIPARUM; MALE; MEROZOITE SURFACE PROTEIN 1; MIDDLE AGED; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PROTOZOAN PROTEINS; YOUNG ADULT;

EID: 84887088903     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-12-403     Document Type: Article

References (31)

1. Artemisinin-resistant malaria in Asia. Noedl H, Socheat D, Satimai W, N Engl J Med 2009 361 540 541 10.1056/NEJMc0900231 19641219
2. Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study. Phyo AP, Nkhoma S, Stepniewska K, Ashley EA, Nair S, McGready R, ler Moo C, Al-Saai S, Dondorp AM, Lwin KM, Singhasivanon P, Day NP, White NJ, Anderson TJ, Nosten F, Lancet 2012 379 1960 1966 10.1016/S0140-6736(12)60484-X 22484134
3. WHO, Global Report on Antimalarial Drug Efficacy and Drug Resistance: 2000-2010 Geneva: World Health Organization 2010
4. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Duong S, Nguon C, Chuor CM, Saunders D, Se Y, Lon C, Fukuda MM, Amenga-Etego L, Hodgson AV, Asoala V, Imwong M, Takala-Harrison S, Nosten F, Su XZ, Ringwald P, Ariey F, Dolecek C, Hien TT, Boni MF, et al. Nat Genet 2013 45 648 655 10.1038/ng.2624 23624527
5. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Takala-Harrison S, Clark TG, Jacob CG, Cummings MP, Miotto O, Dondorp AM, Fukuda MM, Nosten F, Noedl H, Imwong M, Bethell D, Se Y, Lon C, Tyner SD, Saunders DL, Socheat D, Ariey F, Phyo AP, Starzengruber P, Fuehrer HP, Swoboda P, Stepniewska K, Flegg J, Arze C, Cerqueira GC, Silva JC, Ricklefs SM, Porcella SF, Stephens RM, Adams M, et al. Proc Natl Acad Sci U S A 2013 110 240 245 10.1073/pnas.1211205110 23248304
6. The use of PCR genotyping in the assessment of recrudescence or reinfection after antimalarial drug treatment. Snounou G, Beck HP, Parasitol Today 1998 14 462 467 10.1016/S0169-4758(98)01340-4 17040849 (Pubitemid 28539852)
7. The use of genotyping in antimalarial clinical trials: a systematic review of published studies from 1995-2005. Collins WJ, Greenhouse B, Rosenthal PJ, Dorsey G, Malar J 2006 5 122 10.1186/1475-2875-5-122 17169157 (Pubitemid 46020967)
8. WHO, Methods and Techniques for Clinical Trials on Antimalarial Drug Efficacy: Genotyping to Identify Parasite Populations Geneva, Switzerland: World Health Organization 2008
9. Genotyping of plasmodium spp. Nested PCR. Snounou G, Methods Mol Med 2002 72 103 116 12125106
10. Nested PCR analysis of plasmodium parasites. Snounou G, Singh B, Methods Mol Med 2002 72 189 203 12125116
11. Genotyping of Plasmodium falciparum isolates by the polymerase chain reaction and potential uses in epidemiological studies. Viriyakosol S, Siripoon N, Petcharapirat C, Petcharapirat P, Jarra W, Thaithong S, Brown KN, Snounou G, Bull World Health Organ 1995 73 85 95
12. Biased distribution of msp1 and msp2 allelic variants in Plasmodium falciparum populations in Thailand. Snounou G, Xinping Z, Napaporn S, Jarra W, Thaithong S, Brown KN, Viriyakosol S, Trans R Soc Trop Med Hyg 1999 93 369 374 10.1016/S0035-9203(99)90120-7 10674079 (Pubitemid 29405860)
13. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in southeast Asia. Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, Rutvisuttinunt W, Bethell D, Surasri S, Fukuda MM, Socheat D, Chanthap L, Clin Infect Dis 2010 51 82 e89 10.1086/657120 21028985
14. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, Darapiseth S, Teja-Isavadharm P, Khemawoot P, Schaecher K, Ruttvisutinunt W, Lin J, Kuntawungin W, Gosi P, Timmermans A, Smith B, Socheat D, Fukuda MM, PLoS One 2011 6 19283 10.1371/journal.pone.0019283 21603629
15. WHO, Methods for Surveillance of Antimalarial Drug Efficacy Geneva: World Health Organization 2009
16. Daily dynamics of Plasmodium falciparum subpopulations in asymptomatic children in a holoendemic area. Färnert A, Snounou G, Rooth I, Björkman A, Am J Trop Med Hyg 1997 56 538 547 9180605 (Pubitemid 27230077)
17. Complexity of Plasmodium falciparum clinical samples from Uganda during short-term culture. Nsobya SL, Kiggundu M, Joloba M, Dorsey G, Rosenthal PJ, J Infect Dis 2008 198 1554 1557 10.1086/592506 18808336
18. Clearance of asymptomatic P. falciparum infections interacts with the number of clones to predict the risk of subsequent malaria in Kenyan children. Liljander A, Bejon P, Mwacharo J, Kai O, Ogada E, Peshu N, Marsh K, Farnert A, PLoS One 2011 6 16940 10.1371/journal.pone.0016940 21383984
19. Plasmodium falciparum merozoite surface protein 1 (MSP1): genotyping and humoral responses to allele-specific variants. Ekala MT, Jouin H, Lekoulou F, Issifou S, Mercereau-Puijalon O, Ntoumi F, Acta Trop 2002 81 33 46 10.1016/S0001-706X(01)00188-7 11755430 (Pubitemid 34033711)
20. A prospective study of Plasmodium falciparum multiplicity of infection and morbidity in Tanzanian children. Henning L, Schellenberg D, Smith T, Henning D, Alonso P, Tanner M, Mshinda H, Beck HP, Felger I, Trans R Soc Trop Med Hyg 2004 98 687 694 10.1016/j.trstmh.2004.03.010 15485698 (Pubitemid 39345146)
21. Genetic analysis of circulating and sequestered populations of Plasmodium falciparum in fatal pediatric malaria. Montgomery J, Milner DA Jr, Tse MT, Njobvu A, Kayira K, Dzamalala CP, Taylor TE, Rogerson SJ, Craig AG, Molyneux ME, J Infect Dis 2006 194 115 122 10.1086/504689 16741890
22. Misclassification of drug failures in Plasmodium falciparum clinical trials in Southeast Asia. Juliano JJ, Ariery F, Sem R, Tangpukdee N, Krudsood S, Olson C, Looareesuwan S, Rogers WO, Wongsrichanalai C, Meshnick SR, J Infect Dis 2009 200 624 628 10.1086/600892 19591576
23. Estimating true antimalarial efficacy by heteroduplex tracking assay in patients with complex Plasmodium falciparum infections. Kwiek JJ, Alker AP, Wenink EC, Chaponda M, Kalilani LV, Meshnick SR, Antimicrob Agents Chemother 2007 51 521 527 10.1128/AAC.00902-06 17116685 (Pubitemid 46185269)
24. Artemisinin-induced dormancy in Plasmodium falciparum: duration, recovery rates, and implications in treatment failure. Teuscher F, Gatton ML, Chen N, Peters J, Kyle DE, Cheng Q, J Infect Dis 2010 202 1362 1368 10.1086/656476 20863228
25. Phenotypic changes in artemisinin-resistant Plasmodium falciparum lines in vitro: evidence for decreased sensitivity to dormancy and growth inhibition. Teuscher F, Chen N, Kyle DE, Gatton ML, Cheng Q, Antimicrob Agents Chemother 2012 56 428 431 10.1128/AAC.05456-11 21986828
26. Plasmodium falciparum clonal population dynamics during malaria treatment. Jafari S, Le Bras J, Bouchaud O, Durand R, J Infect Dis 2004 189 195 203 10.1086/380910 14722883 (Pubitemid 38147242)
27. Limited advantage of multiple consecutive samples for genotyping Plasmodium falciparum populations during the first days of treatment. Färnert A, Björkman A, Am J Trop Med Hyg 2005 73 204 206 16014859 (Pubitemid 41278773)
28. Only viable parasites are detected by PCR following clearance of rodent malarial infections by drug treatment or immune responses. Jarra W, Snounou G, Infect Immun 1998 66 3783 3787 9673262 (Pubitemid 28347837)
29. Why do we need to know more about mixed Plasmodium species infections in humans? Zimmerman PA, Mehlotra RK, Kasehagen LJ, Kazura JW, Trends Parasitol 2004 20 440 447 10.1016/j.pt.2004.07.004 15324735 (Pubitemid 39485679)
30. Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Slater M, Kiggundu M, Dokomajilar C, Kamya MR, Bakyaita N, Talisuna A, Rosenthal PJ, Dorsey G, Am J Trop Med Hyg 2005 73 256 262 16103584 (Pubitemid 41278693)
31. Influence of consecutive-day blood sampling on polymerase chain reaction-adjusted parasitological cure rates in an antimalarial-drug trial conducted in Tanzania. Martensson A, Ngasala B, Ursing J, Isabel Veiga M, Wiklund L, Membi C, Montgomery SM, Premji Z, Färnert A, Björkman A, J Infect Dis 2007 195 597 601 10.1086/510910 17230421 (Pubitemid 46214404)